Darifenacin
Clinical data | |
---|---|
Trade names | Enablex, Emselex |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605039 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 15 to 19% (dose-dependent) |
Protein binding | 98% |
Metabolism | Liver (CYP2D6- and CYP3A4-mediated) |
Elimination half-life | 13 to 19 hours |
Excretion | Kidney (60%) and biliary (40%) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder.[1][2][3] It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010, the US rights were sold to Warner Chilcott for US$400 million.
Adverse effects
Darifenacin should not be used in people with
Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment.[4]
Medical uses
Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults. It may also be recommended with an
benign prostatic hypertrophy. [5]
Mechanism of action
Darifenacin works by blocking the M3
urinate.[6] It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.[4]
References
- S2CID 41549419.
- S2CID 39061659.
- PMID 18982920.
- ^ a b "Enablex- darifenacin tablet, extended release". DailyMed. 24 September 2016. Retrieved 22 October 2020.
- ^ American Urological Association (AUA) Guideline. Diagnosis and Treatment of Overactive Bladder in Adults: AUA/SUFA guideline 2012
- S2CID 19259076.
External links
- "Darifenacin". Drug Information Portal. U.S. National Library of Medicine.
- "Darifenacin hydrobromide". Drug Information Portal. U.S. National Library of Medicine.